ADC Therapeutics SA Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used
ADC Therapeutics SA (ADCT) reported Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used of $46.00 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-15.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed · last filed 2023-03-15
| Period end | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 12 month |
|---|---|
| 2022-12-31 | $46.00K 20-F · filed 2023-03-15 |
| 2021-12-31 | $164.00K 20-F · filed 2023-03-15 |
| 2020-12-31 | $277.00K 20-F · filed 2022-03-17 |
| 2019-12-31 | $28.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |